Explore Myostatin dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
Products sold as 'Myostatin' are usually follistatin- or propeptide-derived fragments meant to block myostatin — the body's brake on muscle growth — not myostatin itself. They ship as a lyophilized powder, so what's actually in the vial is the key question.
Endogenous myostatin is a secreted TGF-β-superfamily ligand that binds activin receptor type IIB (ActRIIB) and to a lesser extent ActRIIA, recruiting ALK4/5, phosphorylating Smad2/3 and producing transcriptional suppression of muscle-protein synthesis and satellite-cell activity.[1][5] Therapeutic strategies have targeted this pathway by neutralising myostatin (Trevogrumab/REGN1033, Domagrozumab/PF-06252616, Stamulumab/MYO-029), blocking the receptor itself (Bimagrumab/BYM338), or providing a soluble decoy receptor (ACE-031, Acvr2b-Fc), with follistatin gene therapy taking the up-stream-inhibitor approach.
No regulatory approvals for any myostatin-pathway therapy. Multiple Phase 2 and Phase 3 programmes targeting the myostatin pathway in Duchenne muscular dystrophy, sarcopenia, sporadic inclusion-body myositis (sIBM), and obesity have either failed their primary endpoint or been discontinued for safety reasons (see Trevogrumab, ACE-031, and Bimagrumab entries).[4][5][5] **Typical dose:** There is no validated human dose for any unapproved "myostatin" research peptide because no such product has been the subject of a registered clinical trial. The clinical-development pharmacology in the field is described under the individual entries for Trevogrumab, ACE-031, and Follistatin 344.
"Myostatin" as a research-peptide product is a misnomer — endogenous myostatin is the target of inhibition, not a therapeutic itself. Multiple anti-myostatin programmes have failed Phase 2/3.
Myostatin has a reported half-life of ~few hours (estimated). The pharmacokinetic reference models an interval of once daily / every other day; this is not a measured community cadence or a dosing recommendation. Myostatin-pathway peptides have short plasma exposure with no established human PK, so dosing is frequent and the effect tracks the dose rather than a steady accumulated level. Pharmacokinetic source: No established human PK for myostatin (GDF-8) peptide products; estimate. It is catalogued under Muscle Peptides on WPA.
The WPA community has not yet logged enough Myostatin calculator sessions to publish dose, vial size, or bacteriostatic water distributions for it. This page therefore covers what is known about the compound itself; the usage charts fill in as researchers run the calculator.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.